Nuclear Medicine Imaging and Therapy in Breast Cancer

A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Medical Imaging and Theranostics".

Deadline for manuscript submissions: 31 December 2024 | Viewed by 3010

Special Issue Editors

Department of Nuclear Medicine PET/CT Centre, S. Maria della Misericordia Hospital, 45100 Rovigo, Italy
Interests: molecular imaging; PET; breast cancer; prostate cancer; neuroendocrine tumors
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Nuclear Medicine Unit, Veneto Institute of Oncology IOV-IRCCS, 35128 Padua, Italy
Interests: molecular imaging; nuclear medicine; lung cancer; prostate cancer; neuroendocrine tumors; PET/CT; PET/MRI; lymphoma; radioligand therapy
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

We are pleased to invite you to submit a manuscript to this Special Issue of Diagnostics entitled “Nuclear Medicine Imaging and Therapy in Breast Cancer”. Breast cancer is the most prevalent cancer among women worldwide. Nuclear medicine imaging plays a key role in many clinical settings of breast cancer, with numerous radiotracers available or under investigation. Such advancements in diagnostic imaging and therapy, together with the introduction of artificial intelligence technology in clinical practice, will accelerate the advent of truly personalized medicine.

In this Special Issue of Diagnostics, we plan to address the complexity of molecular imaging and theranostics in breast cancer. We prioritize high-quality original studies, encourage the submission of multidisciplinary works, and welcome well-designed meta-analyses and reviews.

Dr. Luca Urso
Dr. Priscilla Guglielmo
Dr. Laura Evangelista
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • breast cancer
  • 18F-FDG PET/CT or PET/MRI
  • 18F-FES PET/CT
  • theranostics
  • beta-based therapy
  • alpha-based therapy
  • radiomics and artificial intelligence
  • alternative radiotracers
  • 68Ga-FAPI or 18F-FAPI PET/CT

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Other

12 pages, 2950 KiB  
Article
The Predictive Role of Radiomics in Breast Cancer Patients Imaged by [18F]FDG PET: Preliminary Results from a Prospective Cohort
by Fabrizia Gelardi, Lara Cavinato, Rita De Sanctis, Gaia Ninatti, Paola Tiberio, Marcello Rodari, Alberto Zambelli, Armando Santoro, Bethania Fernandes, Arturo Chiti, Lidija Antunovic and Martina Sollini
Diagnostics 2024, 14(20), 2312; https://doi.org/10.3390/diagnostics14202312 - 17 Oct 2024
Viewed by 844
Abstract
Background: Recently, radiomics has emerged as a possible image-derived biomarker, predominantly stemming from retrospective analyses. We aimed to prospectively assess the predictive role of [18F]FDG-PET radiomics in breast cancer (BC). Methods: Patients affected by stage I–III BC eligible for neoadjuvant chemotherapy [...] Read more.
Background: Recently, radiomics has emerged as a possible image-derived biomarker, predominantly stemming from retrospective analyses. We aimed to prospectively assess the predictive role of [18F]FDG-PET radiomics in breast cancer (BC). Methods: Patients affected by stage I–III BC eligible for neoadjuvant chemotherapy (NAC) staged with [18F]FDG-PET/CT were prospectively enrolled. The pathological response to NAC was assessed on surgical specimens. From each primary breast lesion, we extracted radiomic PET features and their predictive role with respect to pCR was assessed. Uni- and multivariate statistics were used for inference; principal component analysis (PCA) was used for dimensionality reduction. Results: We analysed 93 patients (53 HER2+ and 40 triple-negative (TNBC)). pCR was achieved in 44/93 cases (24/53 HER2+ and 20/40 TNBC). Age, molecular subtype, Ki67 percent, and stage could not predict pCR in multivariate analysis. In univariate analysis, 10 radiomic indices resulted in p < 0.1. We found that 3/22 radiomic principal components were discriminative for pCR. Using a cross-validation approach, radiomic principal components failed to discriminate pCR groups but predicted the stage (mean accuracy = 0.79 ± 0.08). Conclusions: This study shows the potential of PET radiomics for staging purposes in BC; the possible role of radiomics in predicting the pCR response to NAC in BC needs to be further investigated. Full article
(This article belongs to the Special Issue Nuclear Medicine Imaging and Therapy in Breast Cancer)
Show Figures

Figure 1

Other

Jump to: Research

23 pages, 5274 KiB  
Systematic Review
Radioactive Seed Localization for Nonpalpable Breast Lesions: Systematic Review and Meta-Analysis
by Hortência H. J. Ferreira, Carla Daruich de Souza, Lorena Pozzo, Martha S. Ribeiro and Maria Elisa C. M. Rostelato
Diagnostics 2024, 14(4), 441; https://doi.org/10.3390/diagnostics14040441 - 17 Feb 2024
Cited by 2 | Viewed by 1663
Abstract
Background: This study is a systematic review with meta-analysis comparing radioactive seed localization (RSL) versus radio-guided occult lesion localization (ROLL) and wire-guided localization (WGL) for patients with impalpable breast cancer undergoing breast-conserving surgery and evaluating efficacy, safety, and logistical outcomes. The protocol is [...] Read more.
Background: This study is a systematic review with meta-analysis comparing radioactive seed localization (RSL) versus radio-guided occult lesion localization (ROLL) and wire-guided localization (WGL) for patients with impalpable breast cancer undergoing breast-conserving surgery and evaluating efficacy, safety, and logistical outcomes. The protocol is registered in PROSPERO with the number CRD42022299726. Methods: A search was conducted in the Embase, Lilacs, Pubmed, Scielo, Web of Science, and clinicaltrials.gov databases, in addition to a manual search in the reference list of relevant articles, for randomized clinical trials and cohort studies. Studies selected were submitted to their own data extraction forms and risk of bias analysis according to the ROB 2 and ROBINS 1 tools. A meta-analysis was performed, considering the random effect model, calculating the relative risk or the mean difference for dichotomous or continuous data, respectively. The quality of the evidence generated was analyzed by outcome according to the GRADE tool. Overall, 46 articles met the inclusion criteria and were included in this systematic review; of these, 4 studies compared RSL and ROLL with a population of 1550 women, and 43 compared RSL and WGL with a population of 19,820 women. Results: The results showed that RSL is a superior method to WGL in terms of surgical efficiency in the impalpable breast lesions’ intraoperative localization, and it is at least equivalent to ROLL. Regarding security, RSL obtained results equivalent to the already established technique, the WGL. In addition to presenting promising results, RSL has been proven to be superior to WGL and ROLL technologies. Full article
(This article belongs to the Special Issue Nuclear Medicine Imaging and Therapy in Breast Cancer)
Show Figures

Figure 1

Back to TopTop